scholarly journals The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings

2020 ◽  
Vol 130 ◽  
pp. 110596
Author(s):  
Alberto Mazza ◽  
Danyelle M. Townsend ◽  
Gioia Torin ◽  
Laura Schiavon ◽  
Alessandro Camerotto ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
Chronic Heart Failure ◽  
Ejection Fraction ◽  
Real World ◽  
Hypertensive Patients ◽  
Reduced Ejection Fraction

scholarly journals The therapeutic role of ivabradine in heart failure

2018 ◽  
Vol 9 (11) ◽  
pp. 199-207 ◽  
Author(s):  
Charles Badu-Boateng ◽  
Robert Jennings ◽  
Daniel Hammersley
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Clinical Trials ◽  
Ejection Fraction ◽  
Sinoatrial Node ◽  
Review Article ◽  
Clinical Use ◽  
Symptomatic Heart Failure ◽  
Reduced Ejection Fraction

Heart failure represents a major global cause of morbidity and mortality. Ivabradine is a selective funny current (If) inhibitor, which acts on the sinoatrial node, resulting in a reduction in heart rate. Ivabradine is currently licensed for use in patients with symptomatic heart failure with reduced ejection fraction and a heart rate persistently at least 70 beats per minute in spite of otherwise optimal prognostic heart failure pharmacotherapy. In this review article, we examine the mechanism of action of ivabradine, evaluate the clinical trials underpinning its application in heart failure and discuss its current recommended clinical use in this capacity.

Sign in / Sign up

Export Citation Format

Share Document